Abstract
These studies assessed the gastrointestinal tolerability and cyclooxygenase (COX) selectivity of nimesulide in animals and man. Nimesulide (15 and 30 mg/kg) had no significant 'topical' toxicity in animals as assessed by in vivo mitochondrial morphologcal studies and no increase in small intestinal permeability or inflammation in rats. Similarly, these doses did not affect mucosal prostaglandins significantly and there were no ulcers. At the very high does of 60 mg/kg, nimesulide had some 'topical' toxicity and lost some of its COX-2 selectivity, but this was not associated with inflammation or ulcers. Indomethacin (10 mg/kg, equivalent to 15 mg/kg of nimesulide) altered all of the above parameters and led to small bowel ulcers. This suggests that the gastrointestinal tolerability of nimesulide is not only due to its COX-2 selectivity, but that it is also due to its lack of 'topical' toxicity. Thirty six healthy subjects participated in a randomised, double-blind, double-dummy crossover study (14 day treatment with a washout) of the effect of nimesulide (100 mg bid) and naproxen (500 mg bid) on the gastroduodenal mucosa and small intestine (absorption-permeability and inflammation). An assessment was also made on their COX selectivity. Nimesulide caused significantly less gastric (p = 0.0001) and duodenal (p = 0.0086) damage than naproxen. Naproxen increased intestinal permeability significantly (p = 0.004) and caused intestinal inflammation while nimesulide (p > 0.40) did not. Nimesulide had no significant (p > 0.1) effect on COX-1 dependant platelet aggregation, reduced serum thromboxane B2 levels moderately by 24-34% (p < 0.005) and decreased prostanoid generation in gastric biopsies by 9-30% (p > 0.5). By comparison, naproxen had significantly (p < 0.0001) greater effects on these functions: abolished platelet aggregation to arachidonic acid, suppressed serum thromboxane B2 levels by 98% and gastric prostaglandin production by 76-82%. Nimesulide inhibited lipopolysaccharide-induced PGE2 formation in whole blood to a significantly (p < 0.01) greater extent than naproxen. ___TAGSTART___BR___TAGEND___This study shows that nimesulide has a preferential selectivity for COX-2 over COX-1 in vivo at full therapeutic doses. This selectivity is associated with minimal gastrointestinal damage in the short term.
REFERENCES
L. Aabakken, S. Larsen and M. Osnes (1990). Visual analogue scales for endoscopic evaluation of nonsteroidal anti-inflammatory drug-induced mucosal damage in the stomach and the duodenum, Scand. J. Gastroenterology 25, 443–448.
A. Anthony, C. Trasivoulou, A. P. Dhillon, et al. (1995). Pre-ulcerative villous contraction and microvascular occlusion induced by indomethacin in the rat jejunum, Aliment. Pharmacol. Ther. 9, 605–613.
I. Bjarnason, J. Hayllar, A. J. Macpherson, et al. (1993). Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine, Gastroenterology 104, 1832–1847.
I. Bjarnason, A. J. M. Macpherson and D. Hollander (1995). Intestinal permeability: An overview, Gastroenterology 108, 1566–1581.
I. Bjarnason, P. Smethurst, G. C. Fenn, et al. (1989). Misoprostol reduces indomethacin induced changes in human small intestinal permeability, Dig. Dis. Sci. 34, 407–411.
R. Langenbach, S. G. Morham, H. F. Tiano, et al. (1995). Prostaglandin synthase 1 gene disruption in mice reduced arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration, Cell 83, 483–492.
T. Mahmud, S. S. Rafi, D. L. Scott, et al. (1996). Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation, Arth. Rheum. 39, 1998–2003.
G. Nygard, A. Anthony, C. Piasecki, et al. (1994). Acute indomethacin-induced jejunal injury in the rat: Early morphological and biochemical changes, Gastroenterology 106, 567–575.
G. Sigthorsson, M. Jacob, J. M. Wrigglesworth, et al. (1998). A comparison of indomethacin and nimesulide, a selective cyclooxygenase-2 inhibitor, on key pathophysiological steps in the pathogenesis of NSAID enteropathy in the rat, Scand. J. Gastroenterol. 33, 728–735.
G. Sigthorsson, J. Tibble, J. Hayllar, et al. (1998). Intestinal permeability and inflammation in patients on NSAIDs, Gut. 43, 506–511.
S. Somasundaram, J. Hayllar, S. Rafi, et al. (1995). The biochemical basis of NSAID-induced damage to the gastrointestinal tract: A review and a hypothesis, Scand. J. Gastroenterol. 30, 289–299.
S. Somasundaram, S. Rafi, J. Hayllar, et al. (1997). Mitochondrial damage: A possible mechanism of the ‘topical’ phase of NSAID-induced injury to the rat intestine, Gut. 41, 344–353.
J. Svensson and K. Samuelson (1983). Inhibition of platelet function by low dose acetylsalicylic acid in patients with cardiovascular disease, Thrombosis 31, 499–503.
K. F. Swingle, G. G. I. Moore and T. J. Grant (1976). 4-Nitro-2-phenoxymethanesulfonanilide (R-805): a chemically novel anti-inflammatory agent, Arch. Int. Pharmacodyn. 221, 132–139.
J. Tibble, G. Sigthorsson, R. Foster, et al. (1999). Faecal calprotectin: A simple method for the diagnosis of NSAID-induced enteropathy, Gut. 45, 362–366.
O. Tofanetti, I. Casciarri, P. V. Cipolla, et al. (1989). Effect of nimesulide on cyclo-oxygenase activity in rat gastric mucosa and inflammatory exudate, Med. Sci. Res. 17, 745–746.
G. P. Velo (1991). The anti-inflammatory, analgesic and antipyretic activity of nimesulide in experimental models, Drug Investigation 3 (Suppl. 3), 10–13.
Rights and permissions
About this article
Cite this article
Sigthorsson, G., Thjodleifsson, B., Mahmud, T. et al. Gastrointestinal tolerability of nimesulide, a selective cyclooxygenase-2 inhibitor, in experimental animals and man. Inflammopharmacology 8, 175–187 (2000). https://doi.org/10.1163/15685600038215
Issue Date:
DOI: https://doi.org/10.1163/15685600038215